Nancy Bhatt

Nancy Bhatt has been instrumental in developing ImmTAC bispecific molecules that combine high-affinity TCR domains with anti-CD3 to redirect T cells against solid tumors. Her work contributed to the approval of tebentafusp, the first TCR bispecific approved for uveal melanoma, providing a new treatment paradigm for this rare disease. She has advanced next-generation ImmTAC molecules targeting various tumor antigens presented on MHC. Her research demonstrates the therapeutic potential of soluble high-affinity TCR-based formats for solid tumor treatment.